生命科学资讯

Kyowa Kirin ends OX40 trials after Amgen balked, safety concern

Angitia raises $130M to challenge Amgen with bone-building bispecifics

Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan

Amgen advances toward lupus redemption while gastric cancer candidate struggles

FDA seeks withdrawal of Amgen's Tavneos, company says it won't pull drug

Amgen quits Kyowa Kirin deal, returns rocatinlimab

Amgen gives up on its once-prized eczema drug

Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program

JPM26, Day 2: Amgen touts MariTide's showing in exploratory weight loss maintenance study

Amgen dances with Disco in $618M cancer target pact

Cancer biotech Disco lines up Amgen as first pharma partner

Amgen buys protein-degrading startup Dark Blue for up to $840M

Amgen stitches new acquisition worth up to $840M for UK biotech and its cancer programs

Amgen to acquire Dark Blue Therapeutics for up to $840M

FDA broadens label for Amgen's Uplizna as it enters rare disease competition

Amgen obesity marketing leader Chris Boulton takes reins at metabolic biotech Prolynx

Weight loss biotech Prolynx gets $70M, snags Amgen's obesity commercial leader as CEO

Amgen describes new GTPase KRAS mutant inhibitors

Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syngenta, Biocon, Biogen, F. Hoffmann-La Roche, Novartis, Novo Nordisk A/S, Pfizer, and Seagen - ResearchAndMarkets.com - Business Wire

Cytiva Subsidiary Seeks to Quash Subpoena Issued in Amgen’s US Denosumab Litigation Against Accord & Intas - Pearce IP